Skip to content

Interaction of Muscle Dystrophy, Glucose Metabolism and Insulin Sensitivity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05052073
Acronym
MyoMet
Enrollment
60
Registered
2021-09-22
Start date
2009-09-01
Completion date
2022-12-31
Last updated
2021-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Various Forms of Skeletal Muscle Dystrophy

Keywords

muscle dystrophy, energy metabolism, calorimetry, metabolic chamber, microdialysis, exercise

Brief summary

The aim of this project to characterize systemic and organ-specific (subcutaneous adipose tissue and skeletal muscle) metabolic responses at rest and during standardized, moderate exercise after an oral glucose load in patients with various geneticaly heritable foms of skeletal muscle dystrophies. Metabolic responses will be monitored by indirect calorimetry (canopy and/or metabolic chamber at rest and during exercise) and microdialysis (adipose tissue and skeletal muscle at rest) before and after an oral glucose load (75 g).

Interventions

DIAGNOSTIC_TESToral glucose load at rest

oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.

DIAGNOSTIC_TESToral glucose load and exercise

oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* controls: healthy, no metabolic, endocrine, neurologic or other diseases * patients: genetically confirmed diagnosis of muscle dystrophy

Exclusion criteria

* known hemorrhagic diseases / coagulopathies * intake of oral anti-coagulant drugs (control of PTT, INR and platelet count before study entry) * insulin-dependent Diabetes mellitus * pregnancy and lactation period * chronic use of non-steroidal antiphlogistics * alcohol and drug abuse * Claustrophobia • gleichzeitige Teilnahme an einer anderen Studie; Teilnahme an einer Studie vor weniger als zwei Monaten Unfähigkeit, die mündlichen und schriftlichen Informationen zur Studie zu verstehen und das schriftliche Einverständnis zu geben

Design outcomes

Primary

MeasureTime frameDescription
muscle dialysate lactate15 minutes intervals after glucose over three hoursmarker for anaerobic glycolysis
muscle dialysate pyruvate15 minutes intervals after glucose over three hoursmarker for aerobic glycolysis

Secondary

MeasureTime frameDescription
muscle tissue perfusion15 minutes intervals after glucose over three hoursmeasured by microdialysis and ethanol dial / ethanol perf ratio (no dimensions)
energy expenditure15 minutes intervals after glucose over three hoursmeasured by indirect calorimetry either at rest (canopy device) or during exercise (metabolic chamber)

Countries

Germany

Contacts

Primary ContactMichael Boschmann, Dr. med.
michael.boschmann@charite.de+49.30.450.540.241

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026